Quratis Inc
Quratis Inc is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biopharmaceutical products.
Business. Quratis Inc is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in South Korea and operates within the Pharmaceuticals & Medical Research industry. Quratis is primarily listed on the KOSDAQ exchange under the ticker symbol 348080.KQ. Specific details regarding operating segments and geographic revenue mix are not disclosed.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Quratis Inc is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in South Korea and operates within the Pharmaceuticals & Medical Research industry. Quratis is primarily listed on the KOSDAQ exchange under the ticker symbol 348080.KQ. Specific details regarding operating segments and geographic revenue mix are not disclosed.
Quratis Inc has a capital structure characterized by a debt-to-equity ratio of 0.56, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.66, suggesting that it may struggle to meet short-term obligations with its current assets. The company's cash and equivalents amount to 1,217,559,450 KRW, which is significantly lower than its long-term debt of 18,987,964,430 KRW, resulting in a negative net cash position.
In terms of profitability, Quratis Inc is currently unprofitable, with a return on equity of -13.75% and a return on assets of -7.84%. These figures are well below the industry norms for biotechnology firms, which typically exhibit positive returns on equity and assets. The company's operating income and net income are both negative, at -41,586,958,300 KRW and -4,699,283,590 KRW, respectively, indicating significant operational and financial challenges.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if its primary market or product line experiences a downturn.
Quratis Inc's growth trajectory is currently negative, with a significant decline in revenue and profitability. The company's operating cash flow is -3,478,969,200 KRW, and its free cash flow is -3,725,240,480 KRW, indicating a lack of cash generation and potential liquidity constraints. The company's capital expenditure of -161,053,890 KRW suggests that it is not investing in new projects or expanding its operations.
The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's financial instability. Additionally, the company's unprofitability and negative cash flows may lead to further financial distress if not addressed.
Recent events and filings do not provide specific details on Quratis Inc's strategic initiatives or financial performance beyond the disclosed financial snapshot. The company's financial statements indicate ongoing challenges, but there is no information on recent management actions or strategic changes aimed at improving its financial position.
- Quratis Inc is currently unprofitable with a return on equity of -13.75% and a return on assets of -7.84%.
- The company has a debt-to-equity ratio of 0.56, indicating a moderate reliance on debt financing.
- Quratis Inc has a negative net cash position, with cash and equivalents significantly lower than its long-term debt.
- The company's liquidity position is assessed as medium, with a current ratio of 0.66.
- Quratis Inc is not generating positive cash flows, with both operating and free cash flows being negative.
- "margin_outlook_rationale": "The company's margin outlook is negative due to its unprofitable operations and significant negative gross and operating profits.",
Bull / Bear case
Generated · model-assistedRevenue surged 557.3% year-over-year to KRW 2.46 billion, indicating significant top-line growth momentum.
Operating income improved by 57.0% year-over-year, suggesting a meaningful reduction in operational losses.
Long-term debt decreased to KRW 9.54 billion, reflecting a reduction in leverage compared to prior periods.
Dilution risk is assessed as low, providing some stability for existing shareholders regarding equity structure.
The company maintains a positive book value of KRW 34.17 billion, offering a baseline asset cushion.
Net income remains deeply negative at KRW -29.67 billion, resulting in a severe -68.6% net margin.
Credit risk is flagged as high, signaling significant potential for default or financial distress.
Operating and net margins rank in the bottom quartile among 823 pharmaceutical peers.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Quratis Inc Market data — financials · 2026-05-26